{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:19:45Z","timestamp":1768342785321,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/tpj.2015.100","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T11:01:01Z","timestamp":1453806061000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"M H","family":"Diekstra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Belaustegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J","family":"Swen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Boven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R H","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Rodr\u00edguez-Antona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B I","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-J","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"BFtpj2015100_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/1078-0432.CCR-10-1828","volume":"17","author":"A van der Veldt","year":"2011","unstructured":"van der Veldt A, Eechoute K, Gelderblom H, Gietema J, Guchelaar H-J, van Erp N et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011; 17: 620\u2013629.","journal-title":"Clin Cancer Res"},{"key":"BFtpj2015100_CR2","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","volume":"27","author":"N van Erp","year":"2009","unstructured":"van Erp N, Eechoute K, van der Veldt A, Haanen J, Reyners A, Mathijssen R et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009; 27: 4406\u20134412.","journal-title":"J Clin Oncol"},{"key":"BFtpj2015100_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1470-2045(11)70266-2","volume":"12","author":"J Garcia-Donas","year":"2011","unstructured":"Garcia-Donas J, Esteban E, Leandro-Garcia L, Castellano D, del Alba A, Climent M et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143\u20131150.","journal-title":"Lancet Oncol"},{"key":"BFtpj2015100_CR4","first-page":"503","volume":"92","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, van der Veldt A, Oosting S, Kappers M, Wessels J, Gelderblom H et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 2012; 92: 503\u2013510.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj2015100_CR5","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/cncr.26491","volume":"118","author":"J Kim","year":"2012","unstructured":"Kim J, Vaziri S, Rini B, Elson P, Garcia J, Wirka R et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012; 118: 1946\u20131954.","journal-title":"Cancer"},{"key":"BFtpj2015100_CR6","doi-asserted-by":"crossref","unstructured":"Urun Y, Gray K, Signoretti S, McDermott D, Atkins M, Lampron M et al. Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstr 2013; 31http:\/\/meetinglibrary.asco.org\/content\/113157-132.","DOI":"10.1200\/jco.2013.31.15_suppl.4570"},{"key":"BFtpj2015100_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10096-014-2294-5","volume":"34","author":"H He","year":"2015","unstructured":"He H, Sun J, Ren X, Wang T, Zhai Y, Chen S et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis 2015; 34: 811\u2013819.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"BFtpj2015100_CR8","doi-asserted-by":"publisher","first-page":"e86206","DOI":"10.1371\/journal.pone.0086206","volume":"9","author":"C Li","year":"2014","unstructured":"Li C, Li L, Lin L, Jiang H, Zhong Z, Li W et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS One 2014; 9: e86206.","journal-title":"PLoS One"},{"key":"BFtpj2015100_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/FTD.0b013e31818a2a60","volume":"30","author":"S Crettol","year":"2008","unstructured":"Crettol S, Venetz J-P, Fontana M, Aubert J-D, Pascual M, Eap C et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008; 30: 689\u2013699.","journal-title":"Ther Drug Monit"},{"key":"BFtpj2015100_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2217\/14622416.8.5.443","volume":"8","author":"M Schirmer","year":"2007","unstructured":"Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat M, Nurnberg P et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics J 2007; 8: 443\u2013453.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj2015100_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2015.04.018","volume":"68","author":"M Diekstra","year":"2015","unstructured":"Diekstra M, Swen J, Boven E, Castellano D, Gelderblom H, Mathijssen R et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol 2015; 68: 621\u2013629.","journal-title":"Eur Urol"},{"key":"BFtpj2015100_CR12","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"D Heng","year":"2009","unstructured":"Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794\u20135799.","journal-title":"J Clin Oncol"},{"key":"BFtpj2015100_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ars.2013.5244","volume":"20","author":"S Lankhorst","year":"2014","unstructured":"Lankhorst S, Kappers M, van Esch J, Danser A, van den Meiracker A . Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 2014; 20: 135\u2013145.","journal-title":"Antioxid Redox Signal"},{"key":"BFtpj2015100_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"B Houk","year":"2010","unstructured":"Houk B, Bello C, Poland B, Rosen L, Demetri G, Motzer R et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357\u2013371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj2015100_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2133\/dmpk.DMPK-12-RG-026","volume":"27","author":"T Mizuno","year":"2012","unstructured":"Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O et al. Impact of genetic variation in breast cancer resistance protein (BCRP\/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet 2012; 27: 631\u2013639.","journal-title":"Drug Metab Pharmacokinet"},{"key":"BFtpj2015100_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1248\/bpb.b14-00636","volume":"38","author":"M Nagata","year":"2015","unstructured":"Nagata M, Ishiwata Y, Takahashi Y, Takahashi H, Saito K, Fujii Y et al. Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma. Biol Pharm Bull 2015; 38: 402\u2013410.","journal-title":"Biol Pharm Bull"},{"key":"BFtpj2015100_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","volume":"13","author":"S Noda","year":"2015","unstructured":"Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K et al. Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 2015; 13: 350\u2013358.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"BFtpj2015100_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/tpj.2015.13","volume":"16","author":"Y L Teo","year":"2015","unstructured":"Teo Y, Wee H, Chue X, Chau N, Tan M, Kanesvaran R et al. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J 2015; e-pub ahead of print 17 March 2015; doi:10.1038\/tpj.2015.13.","journal-title":"The Pharmacogenomics Journal"},{"key":"BFtpj2015100_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/clpt.2014.47","volume":"96","author":"M Diekstra","year":"2014","unstructured":"Diekstra M, Kl\u00fcmpen HJ, Lolkema M, Yu H, Kloth J, Gelderblom H et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther 2014; 96: 81\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj2015100_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"B Rini","year":"2011","unstructured":"Rini B, Cohen D, Lu D, Chen I, Hariharan S, Gore M et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763\u2013773.","journal-title":"J Natl Cancer Inst"},{"key":"BFtpj2015100_CR21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3109\/0284186X.2014.918276","volume":"53","author":"B Beuselinck","year":"2014","unstructured":"Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol 2014; 53: 1413\u20131422.","journal-title":"Acta Oncol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj2015100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj2015100","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj2015100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:15:27Z","timestamp":1647947727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj2015100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFtpj2015100"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.100","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,26]]},"assertion":[{"value":"8 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Brian Rini and Garcia-Donas report consulting and research funding from Pfizer. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}